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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high
mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been
approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland
and Sweden. Our study explored potential differences in the care of IPF in these two countries.
Methods: Patients included consecutively in the Finnish and Swedish IPF-registries from January 1, 2014 through
December 31, 2016 were included in the study. Data on demographics and lung function at the time of inclusion
were collected. Access to antifibrotic drugs and data on disease outcomes, mortality and the proportion of patients
who underwent lung transplantation, was collected during a 3-year follow up.
Results: One-hundred and fifty-two patients from the Finnish and 160 patients from the Swedish IPF-cohorts were
included in the study. At inclusion, Finnish patients were significantly older than the Swedish patients (74.6 years vs
72.5 years, p = 0.017). The proportion of non-smokers was significantly higher in the Finnish cohort (41.7% vs 26.9%,
p = 0.007). Forced vital capacity (FVC), % of predicted (78.2 vs 71.7 for Finnish and Swedish patients, respectively,
p = 0.01) and diffusion capacity for carbon monoxide (DLCO), % of predicted (53.3 vs 48.2 for Finnish and Swedish
patients, respectively, p = 0.002) were significantly higher in the Finnish cohort compared to the Swedish cohort at
the time of inclusion. During the 3-year follow up period, 45 (29.6%) Finnish and 111 (69.4%) Swedish patients,
respectively, were initiated on treatment with an antifibrotic drug (pirfenidone or nintedanib) (p < 0.001). When
comparing possible determinants of treatment, patients with higher FVC % were less likely to start antifibrotic drugs
(OR 0.96, 95%CI 0.93–1.00, p < 0.024). To be resident in Sweden was the main determinant for receiving antifibrotic
drugs (OR 5.48, 95%CI 2.65–11.33, p < 0.0001). No significant difference in number of deaths and lung
transplantation during the follow up period was found.
Conclusions: This study highlights differences concerning how IPF patients are treated in Finland and Sweden.
How these differences will influence the long-term outcome of these patients is unknown.
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Background
Idiopathic pulmonary fibrosis (IPF) is the most common
type of the idiopathic interstitial pneumonias (IIP) char-
acterized by a progressive fibrosis and loss of lung func-
tion [1]. Idiopathic pulmonary fibrosis is diagnosed by a
typical radiological finding of usual interstitial pneumo-
nia (UIP) on high resolution computed tomography
(HRCT) or, in some cases, by a histological investigation
of lung biopsy [1]. Two drugs (pirfenidone and ninteda-
nib) have shown to slow down the decline of lung func-
tion in IPF patients, and combined treatments are
currently under clinical investigation [2, 3]. In addition
to drug treatment, early integration of supportive care
and possible lung transplant evaluation are recom-
mended [4, 5].
During the last few years, national registries collecting
clinical data from IPF patients have been established [6–9].
These registries enable prospective follow up of real-life IPF
patients’ disease course. The IPF registry (FinnishIPF) in
Finland was started in 2011 [10] and currently includes
nearly 700 patients. Previous studies on the Finnish IPF
registry revealed that Finnish IPF patients are diagnosed at
an early stage of the disease with mild or moderate loss of
lung function [11]. The Swedish IPF registry was started in
2014 and data on diagnostic evaluations, demographics,
lung function, laboratory tests and quality of life have been
successfully collected since then [7].
There are no previous comparative studies on the real-
life clinical presentation and management of IPF in the
Nordic countries. Finland and Sweden are neighboring
countries with many similarities. Furthermore, there is a
close collaboration between the countries and specialists
from the main university hospitals, and a shared position
paper on the diagnosis and treatment of IPF was
recently published as a first attempt to optimize and
uniform health care for IPF patients in the Nordic
countries [12].
This cohort study was performed to assess whether
IPF shares common presentation in two neighboring
European countries, and whether patients have the
same opportunities in terms of access to health care
and treatment. We compared the main clinical pres-
entation, demographics, lung function and access to
specific treatments in Finland and Sweden using the
respective national registries as source of data.
Methods
The National IPF registries
The Finnish IPF registry was created in 2011 on a
web-based platform (Granitics Unify Med, Granitics
Ltd., Espoo, Finland) and collects today patients from
27 different hospitals across the country. Inclusion
criteria to the registry are patients diagnosed with IPF
[10]. In 2014, the same platform was chosen and
adapted for the Swedish data collection to become
the Swedish IPF registry [7]. Patients are currently
enrolled from 22 different hospitals across Sweden.
The inclusion of IPF patients in both registries is
based on the fulfillment of the main international
diagnostic criteria [1], and informed consent is signed
in both countries upon inclusion.
Demographics, clinical data such as lung function,
comorbidities, radiology, histopathology, prescribed
treatments and outcomes are reported in both regis-
tries [7, 13]. All these variables are duly updated in
both registries by the investigators at site and by two
research nurses in the respective headquarters
(Helsinki in Finland and Stockholm in Sweden) at the
time of inclusion and after every clinical visit usually
between every 3–6 months.
For the aims of this study, only patients included in
the two registries with a diagnosis of IPF from January 1,
2014 to December 31, 2016 were considered. Patients
who received another diagnosis than IPF during the
course of their disease were excluded from this study.
Furthermore, patients treated with antifibrotic drugs be-
fore January 1, 2014 were excluded from the study.
Data collection
Data on age, sex, body mass index (BMI), smoking
habits (smoking status, pack/years), forced vital cap-
acity (FVC, liters and % of predicted), forced expira-
tory volume (FEV1, liters and % of predicted) and
diffusing capacity for carbon monoxide (DLCO, % of
predicted) at the time of inclusion were extracted
from the registries. Percent of predicted values for lung
function were reported with the Finnish reference values
from 1982 [14] in the Finnish registry and with the Swed-
ish reference values in the Swedish registry [15, 16].
Follow up-data were collected during the study period
(January 1, 2014 - December 31, 2016). Information re-
garding the prescription of antifibrotic treatments and
the time between inclusion and start of treatment
(weeks) were collected during this period, as well as data
on outcomes (death and lung transplantation).
Statistical analysis
Gender distribution and smoking habits were presented
as proportions and compared with Chi-squared test be-
tween the Finnish and Swedish cohorts. Data on age,
sex, BMI, smoking habit, FVC, FVC %, FEV1, FEV1%,
DLCO % and time from inclusion to treatment with anti-
fibrotic drugs were presented as mean and standard de-
viation (SD). Parametric and non-parametric statistical
tests (Mann-Whitney test) were used when appropriate
to compare means between the two cohorts.
The nominal data on prescribing a treatment with
antifibrotic drugs during the study period (yes or no)
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was assessed as proportions for the two groups and
compared with Chi-squared test. An univariate analysis
was performed to assess differences between patients re-
ceiving and not receiving a treatment with antifibrotic
drugs. To assess the influence of potential independent
factors (gender, age, lung function, country, type of hos-
pital) on the starting of treatment with antifibrotic drugs
a logistic regression analysis was performed.
All the analyses were performed using the statistical
software SPSS 20.0 (IBM Corp, Armonk, NY, USA).
Results
Registry population
One hundred fifty-eight eligible patients in the Finnish
IPF registry and 174 patients in the Swedish IPF registry
fulfilling the inclusion criteria were included in the
study. Six patients were excluded from the Finnish co-
hort due to another ILD diagnosis during the follow up
(two patients with rheumatoid arthritis, two patients
with hypersensitivity pneumonitis, one with microscopic
polyangitis and one with NSIP). Fourteen IPF patients
from the Swedish cohort were excluded from the ana-
lysis because they were recently transferred to the regis-
tering center from other centers/specialists and were
already on antifibrotic treatment before the inclusion. One
hundred fifty-two and 160 patients from the Finnish and
Swedish cohorts, respectively, were analyzed.
Demographics and lung function
There were no differences in gender distribution and
BMI between the cohorts (Table 1). However, Finnish
patients were significantly older compared to the Swed-
ish patients at inclusion, and the proportion of never
smokers was significantly higher in the Finnish cohort
(Table 1). Nine Finnish patients (5.9%) and 7 Swedish
patients (4.4%) were current smokers (p = 0.54). Forced
vital capacity, % of predicted and DLCO % were
significantly higher in the Finnish cohort compared to
the Swedish cohort (Table 2).
Treatment with antifibrotic drugs
During the follow up period, 45 (29.6%) Finnish and
111 (69.4%) Swedish patients, respectively, were pre-
scribed an antifibrotic drug (pirfenidone or ninteda-
nib, p < 0.001). The mean time from inclusion to drug
treatment was significantly longer in Finland than in
Sweden (26±31.3 vs 5.3±14.4 weeks, p < 0.001). Youn-
ger patients were more likely to receive antifibrotic
drug treatment compared to older patients (Table 3).
Patients in the drug treatment group had also signifi-
cantly lower FVC % and DLCO % compared to the
non-treatment group (Table 3).
A multivariate analysis was performed to explore which
factors were determinants of treatment with antifibrotic
drugs. In particular, FVC % was inversely correlated with
drug treatment (Table 4). The strongest determinant for
starting a treatment was to be resident in Sweden, with an
odds ratio of 5 times for Swedish patients compared to
Finnish patients (Table 4). These results did not change
when a sensitivity analysis was performed taking into ac-
count if the patients were treated at university or periph-
eral hospital (Table 4).
No difference was found in the number of deaths, 34
(22.4%) and 26 (16.3%) among the Finnish and Swedish
patients, respectively (p = 0.17). Neither was there any
differences in the number of patients undergoing lung
transplantation (1 each, 0.01% in both the Finnish and
Swedish cohorts, p = 0.97) during the study period.
Discussion
Our study demonstrates significant differences in the
clinical characteristics and initiation of treatment with
antifibrotic drugs in IPF in two neighboring Nordic
countries based on those subjects included into the IPF-
registries. Finnish IPF patients were older, had better
lung function, were less likely to have smoked and were
prescribed less antifibrotic drugs compared to Sweden.
The better lung function in Finnish patients at the point
of inclusion may be a result of diagnosis at an earlier stage
Table 1 Demographics of the study population extracted from







Female n (%) 95 48 (31.6) 47 (29.4) 0.672
Male n (%) 217 104 (68.4) 113 (70.6)
Age at inclusion mean (SD) 312 74.6 (8.3) 72.5 (8.0) 0.017
BMIa, kg/m2, mean (SD) 268 28.5 (5.5) 27.1 (4) 0.083
Smoking habits
Never smoker n (%) 102 63 (41.7) 39 (26.9) 0.007
Ex or current smoker n (%) 195 88 (58.3) 106 (73.1)
Pack/years mean (SD) 144 24.4 (13.7) 24 (14.8) 0.716
Definitions on abbreviations: aBMI Body Mass Index; SD standard deviation
Table 2 Lung function at inclusion in the IPF patients extracted









a, % predicted, mean (SD) 288 77.7 (19.4) 77.2 (17.1) 0.817
FVCb, L, mean (SD) 278 2.71 (0.84) 2.76 (0.83) 0.614
FVC, % predicted, mean (SD) 283 78.2 (17.7) 71.7 (16) 0.010
DLCO
c, % predicted, mean (SD) 238 53.3 (14.4) 48.2 (14.7) 0.002
Definitions on abbreviations: aFEV1 Forced expiratory volume;
bFVC Forced
vital capacity; cDLCO Diffusing capacity of carbon monoxide; SD
standard deviation
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of the disease compared to Swedish patients. The propor-
tion of ex- or current- smokers in both countries was
lower than what was previously shown with e.g. Danish
patients, where a cohort study showed that 81% of the pa-
tients were ex- or current- smokers [17].
A previous study showed that organization of specific
services can vary among different Nordic countries and
within countries, depending on resources and local
guidelines [18]. Finland and Sweden are neighboring
countries with many similarities but also marked differ-
ences in health care systems. It is shown that there are
significant genetic differences between these two popula-
tions but also within Finland between subpopulations in
Eastern and Western Finland [19, 20].
Our study shows that there are differences in how pa-
tients are treated with antifibrotic drugs in Finland and
Sweden. Close to 30% of Finnish patients started treat-
ment compared to nearly 70% of the patients in Sweden.
Although nintedanib reached the markets in 2015, there
was no difference in the availability of drugs in the two
countries during the study period; pirfenidone was intro-
duced in Sweden in 2011 and in Finland in 2013, way
before our study started. However, nor of the registries
have a full coverage of the IPF population in each coun-
try, and therefore the bias of selection of the patients
may have some effect to the results. It is to note, anyway,
that all the university hospitals and all the main periph-
eral hospitals are actively reporting patients in Finland
and Sweden.
Therefore, we report a consistent and significant dif-
ference in the use of antifibrotic drugs in Finland and
Sweden, not explained by the availability of the drugs on
the market. Differences in reimbursement systems be-
tween these two countries could account for this differ-
ence. The prescription of drugs in Finland is regulated
by the social insurance institution of Finland. Patients
with IPF are required to have a FVC % value between 50
and 90% to receive the drugs at lower costs, but still
need to pay an annual cost of over six hundred Euros.
Furthermore, until 2015, the upper limit for FVC % was
80% which means that once reached the markets, antifi-
brotic drugs was not an option for patients with FVC %
over 80% for at least two years. The reimbursement is
applied for every patient and the processing time for ap-
plications can vary between 2 and 6 weeks. On the other
hand, the antifibrotic drugs are included in the general
high-cost protection in Sweden and, therefore, there is
no need to apply for reimbursement, patients can pur-
chase drugs as soon as a physician has made a decision
on drug initiation. A Swedish patient pays no more than
around 230 Euros for drugs entitled to high-cost protec-
tion within a year. Furthermore, since 2012, antifibrotic
drugs can be prescribed in Sweden regardless of the lung
function values.
Previous studies show benefits of treating patients with
mild to moderate loss of lung function [5, 21, 22]. This
study revealed common tendencies of drug prescription
in both countries; Firstly, a lower FVC % seems to favor
treatment, as it does a younger age. Limited studies on
Table 3 Demographics and clinical features of the patients
divided for treatment with antifibrotic drugs






Female n (%) 95 56 (35.9) 39 (25) 0.036
Male n (%) 217 100 (64.1) 117 (75)
Age at inclusion mean (SD) 312 74.9 (8.7) 72.1 (7.4) 0.001
BMIa, kg/m2, mean (SD) 268 27.3 (4.5) 28.1 (5.0) 0.393
Smoking habits
Never smoker n (%) 102 58 (38.4) 54 (30.3) 0.144
Ex or current smoker n (%) 195 93 (61.6) 101 (69.7)
Pack/years mean (SD) 144 24 (14.3) 24.2 (14) 0.851
Lung function tests
FEV1
b, L, mean (SD) 286 2.18 (0.71) 2.20 (0.60) 0.833
FEV1, % predicted, mean (SD) 288 80.1 (20.6) 75 (15.3) 0.040
FVCc, L, mean (SD) 278 2.75 (0.89) 2.73 (0.77) 0.844
FVC, % predicted, mean (SD) 283 79.3 (19.2) 70.5 (13.5) < 0.001
DLCO
d, % predicted, mean (SD) 238 54.7 (14.2) 47.3 (14.5) < 0.001
Country
Finland 152 107 (68.6) 45 (28.8) < 0.001
Sweden 160 49 (31.4) 111 (71.2)
Definitions on abbreviations: aBMI Body Mass Index; bFEV1 Forced expiratory
volume; cFVC Forced vital capacity; dDLCO Diffusing capacity of carbon
monoxide; SD standard deviation
Table 4 Determinants of treatment with antifibrotic drugs,
logistic regression analysis during the study period (January
2014 – December 2016)
Variable ODDS RATIO 95%CI p
Female gender 0.76 0.39–1.48 0.419
Age at inclusion 0.98 0.95–1.02 0.413
FVCa, % predicted 0.96 0.93–1.00 0.024
FEV1
b, % predicted 1 0.97–1.04 0.744
DLCO
c, % predicted 0.98 0.96–1.01 0.171
Country





Definitions on abbreviations: aFEV1 Forced expiratory volume;
bFVC Forced
vital capacity; cDLCO Diffusing capacity of carbon monoxide
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the treatment of patients at the extremes of lung func-
tion (well preserved or severely impaired) and regional
guidelines (allocating resources and priorities at a local
level) are probably two of many reasons affecting the de-
cision to treat with antifibrotic drugs. However, recent
studies show that both patients with preserved lung
function and with a severe loss of lung function may
benefit from treatment [23–25].
During the study period, no significant difference in
disease outcomes was shown. However, we consider the
period as too short and the cohort size as too small to
make any conclusions; a longer follow up period and lar-
ger cohort sizes are needed to show some potential dif-
ferences in either lung function decline or mortality,
even in consideration of the differences in the prescrip-
tion of the treatment.
There are some possible limitations when working with
two independent registries which could contribute to the
differences. We cannot exclude a bias in the recruitment of
patients to the registries in the two countries, i.e. patients
could be recruited in Sweden mostly in university- or refer-
ence centers and they could be more prone to be treated
than in peripheral hospitals in Finland. On the other hand,
the comparison between the university and peripheral hos-
pitals revealed no difference for what concerns treatment
with antifibrotic drugs between these two cohorts.
Finland and Sweden are using different, local reference
values for the lung function tests which could contribute
to the differences in the observed lung function in per
cent of predicted. However, we investigated in this study
which factors did support the decision to treat with
antifibrotic drugs in real-life practice in the two
countries; the real-life reported value of the FVC % of the
predicted value was the main index used by physicians in
both countries, and our study clearly shows that patients
in Finland and Sweden are treated when a big proportion
of lung function is already lost. These findings should
stimulate the discussion about the need of an early diag-
nosis and treatment of IPF.
None of the patients included in the Finnish and
Swedish registries were enrolled in ongoing clinical trials
during the study period. This is an important informa-
tion, as the participation of clinical centers in ongoing
trials could have potentially increased the number of pa-
tients receiving drugs, regardless of local regulations.
Conclusions
This study shows a unique comparative cohort of mod-
ern, high-quality registry data from Finland and Sweden.
Even though these health care systems can be evaluated
as being very similar with predominating public health
care systems, especially for rare diseases, we were able to
pinpoint marked differences in the IPF patients’ access
to antifibrotic therapy. In addition, we were able to
identify differences in population characteristics,
namely patient's smoking habits and age. Data from
both countries suggests that physicians tend to pre-
scribe antifibrotic drugs to patients that are younger
and have a more advanced disease. Further studies
are needed to assess how the inequality in treatment
will affect long-term outcomes such as lung function,
mortality and transplantation rates.
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